Hodgkin Lymphoma, Adult Clinical Trial
Official title:
SPECT Imaging of Lymphoma Using Technetium-99m Labeled 1-Thio-D-Glucose (99mTc-1-thio-D-glucose)
The study should evaluate the biological distribution of 99mTc-1-thio-D-glucose in patients with Hodgkin Lymphoma and Non Hodgkin Lymphoma. The primary objective are: 1. To assess the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc-1-thio-D-glucose. 3. To study the safety and tolerability of the drug 99mTc-1-thio-D-glucose after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained 99mTc-1-thio-D-glucose SPECT imaging results with the data of CT imaging and/or 18F-FDG positron emission tomography (PET) and immunohistochemical (IHC) studies in Lymphoma patients.
The overall goal is to study the effectiveness of SPECT imaging Hodgkin Lymphoma and Non Hodgkin Lymphoma Using technetium-99m labeled 1-thio-D-glucose. Phase I of the study: Biodistribution of 99mTc-1-thio-D-glucose in patients with Hodgkin Lymphoma and Non Hodgkin Lymphoma. The main objectives of the study: 1. To evaluate the distribution of 99mTc-1-thio-D-glucose in normal tissues and tumors in patients with Lymphoma at different time intervals. 2. To evaluate dosimetry of 99mTc-1-thio-D-glucose based on the pharmacokinetic parameters of the drug after a single intravenous administration. 3. To study the safety of use and tolerability of the drug 99mTc-1-thio-D-glucose after a single intravenous administration in a diagnostic dosage. Additional research tasks: 1. To conduct a comparative analysis of the diagnostic information obtained in the visualization of Lymphoma by SPECT using 99mTc-1-thio-D-glucose with data obtained by CT and/or positron emission tomography (PET) and immunohistochemical (IHC) research of postoperative material. Methodology: Open-label, exploratory, single centre study. The subjects will receive a single injection of the labeled tracer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04636255 -
Physical Capacity in Hodgkin Lymphoma Survivors
|
N/A | |
| Recruiting |
NCT05597761 -
Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
|
||
| Active, not recruiting |
NCT03535948 -
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
|
||
| Completed |
NCT03155425 -
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
| Recruiting |
NCT04776265 -
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
|
||
| Recruiting |
NCT04378647 -
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
|
Phase 2 | |
| Recruiting |
NCT04758650 -
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
|
Phase 2 | |
| Recruiting |
NCT05137886 -
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04268706 -
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
|
Phase 2 | |
| Recruiting |
NCT04638790 -
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
|
Phase 3 | |
| Completed |
NCT01578967 -
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
|
N/A | |
| No longer available |
NCT03914885 -
Compassionate Use Re-Infusion of ATLCAR.CD30
|